Cambridgeshire, UK, 24 August 2009: Quotient Bioresearch Limited (Cambridgeshire, UK) (“Quotient”), a leading provider of drug development services, and Clinical Reference Laboratory (“CRL Global Services”), a privately owned reference laboratory based in Kansas, USA offering leading edge clinical laboratory testing services, have concluded an agreement that will result in the provision of a global clinical laboratory testing capability to support the two Group’s clients world wide.
Under the agreement Quotient and CRL Global Services will jointly offer clinical laboratory and other specialist testing services to support clinical development programs for the global pharmaceutical, biotechnology and CRO industries. The established services of the two organisations are entirely complementary, creating considerable benefits for clients from the combined service offering of the two Groups.
Under the collaboration, CRL Global Services will set up its European clinical reference laboratory operation within Quotient’s state-of-the-art facility in Cambridgeshire, UK, establishing it as the European hub for its Central Laboratory Services unit. This will complement Quotient’s existing clinical laboratory services, particularly in the area of bioanalysis and biomarkers.
Paul Cowan, CEO of Quotient Bioresearch commented: “This collaboration brings exciting new opportunities for our bioanalytical sciences and microbiology businesses. Working in tandem with CRL offers access to a well established, standardized global laboratory infrastructure and the ability to serve the requirements of our clients for global clinical trials.”
Tim Sotos, CEO of Clinical Reference Laboratory added “Quotient Bioresearch is an excellent partner for Clinical Reference Laboratory. Quotient’s strong track record in high quality bioanalytical sciences and early phase drug development is highly complementary to our business and offers significant added value in the provision of central laboratory services.”
About Quotient Bioresearch
Quotient is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units – Quotient Radiochemistry & Metabolism, Quotient Bioanalytical Sciences (including Microbiology) and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.
For further information: www.quotientbioresearch.com
About Clinical Reference Laboratory
CRL offers leading edge testing services in the areas of Clinical Trials, Corporate Wellness Programs, Genomics, Insurance, and Toxicology. Analyzing over 100 million tests annually, CRL is one of the largest privately owned laboratories operating on a national basis in the USA. In addition, it has had the same core management group for the past eighteen years.
For further information: www.crlcorp.com
Under the agreement Quotient and CRL Global Services will jointly offer clinical laboratory and other specialist testing services to support clinical development programs for the global pharmaceutical, biotechnology and CRO industries. The established services of the two organisations are entirely complementary, creating considerable benefits for clients from the combined service offering of the two Groups.
Under the collaboration, CRL Global Services will set up its European clinical reference laboratory operation within Quotient’s state-of-the-art facility in Cambridgeshire, UK, establishing it as the European hub for its Central Laboratory Services unit. This will complement Quotient’s existing clinical laboratory services, particularly in the area of bioanalysis and biomarkers.
Paul Cowan, CEO of Quotient Bioresearch commented: “This collaboration brings exciting new opportunities for our bioanalytical sciences and microbiology businesses. Working in tandem with CRL offers access to a well established, standardized global laboratory infrastructure and the ability to serve the requirements of our clients for global clinical trials.”
Tim Sotos, CEO of Clinical Reference Laboratory added “Quotient Bioresearch is an excellent partner for Clinical Reference Laboratory. Quotient’s strong track record in high quality bioanalytical sciences and early phase drug development is highly complementary to our business and offers significant added value in the provision of central laboratory services.”
About Quotient Bioresearch
Quotient is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units – Quotient Radiochemistry & Metabolism, Quotient Bioanalytical Sciences (including Microbiology) and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.
For further information: www.quotientbioresearch.com
About Clinical Reference Laboratory
CRL offers leading edge testing services in the areas of Clinical Trials, Corporate Wellness Programs, Genomics, Insurance, and Toxicology. Analyzing over 100 million tests annually, CRL is one of the largest privately owned laboratories operating on a national basis in the USA. In addition, it has had the same core management group for the past eighteen years.
For further information: www.crlcorp.com
